Ono enters into research collaboration agreement with twoXAR
Under the agreement, twoXAR will use its proprietary artificial intelligence (AI ) technology to identify a set of lead compounds which demonstrate a novel mechanism of action and
BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.
Hereditary Spinocerebellar Ataxias are rare, potentially fatal neurodegenerative disorders affecting the cerebellum. They are characterized clinically by progressive ataxia symptoms, including difficulties with balance, speech, and coordination, and